cabozantinib
ipsen
['rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabopoint', 'cabo ']
as always, a wonderful and important presentation from presenting the cabopoint study, evaluating first efficacy of cabo in patients who received io combination first line. cabo stills shows good efficacy, even in patients with primary refractory tumors #gu23 
Oncologist, physician-scientist, Assistant Professor @YaleCancer @YaleMed | cancer immunotherapy, genomics, kidney cancer | tweets ≠ medical advice.